This hypothesis is supported by the evidence that AKAP9 has been considered as a genetic modifier of congenital LQTS, increasing cardiac risk and disease severity in AKAP9 mutation carriers [80]. The gene discussed is AKAP9; the disease is familial long QT syndrome.